Clinical Trials
Sunday, December 16th, 2012
Radiology: 12/11/12 Purpose: To compare safety and utility of intraarterial revascularization with use of stents to no revascularization in patients who either failed to respond to intravenous thrombolysis (IVT) or have contraindications to IVT. Materials and Methods: The case-control study was approved by local ethics committees; all patients signed informed consent. One hundred thirty-one patients (74 men; mean […]
Clinical Trials
Sunday, December 16th, 2012
AHA: December 11, 2012, Background and Purpose—The reliability of hematoma volume (HV) measurement using the ABC/2 method in multicenter clinical trials is unknown. We determined the accuracy of ABC/2 method as an on-site test in comparison with the gold standard central HV-assessment and semiautomatic HV-assessment. Method—We analyzed data from an acute intracerebral hemorrhage multicenter clinical trial. […]
Clinical Trials
Sunday, December 16th, 2012
AHA: 12/6/12 Background and Purpose—Communication between hospitals and primary care physicians is essential for the continuity of care for patients being transferred from hospital to ambulatory care. Patients are often discharged from hospital on medication regimes different from those used before hospital admission. The aim of the study was to evaluate the adherence to hospital discharge […]
Clinical Trials
Friday, December 7th, 2012
Neurology: 12/5/12 Objective: Beneficial effects of IV tissue plasminogen activator (tPA) in acute ischemic stroke are strongly time-dependent. In the Pre-Hospital Acute Neurological Treatment and Optimization of Medical care in Stroke (PHANTOM-S) study, we undertook stroke treatment using a specialized ambulance, the stroke emergency mobile unit (STEMO), to shorten call-to-treatment time. Methods: The ambulance was staffed with a […]
Clinical Trials
Friday, December 7th, 2012
Wiley: 12/4/12 Objectives Vascular risk factor control may not only prevent stroke but also reduce the risk of dementia. We investigated whether a multifactorial intervention program reduces the incidence of cognitive symptoms one-year after stroke and transient ischemic attack in first ever stroke patients without cognitive decline prior to the stroke. Materials and methods Patients suffering […]
Clinical Trials
Friday, December 7th, 2012
Society of NeuroInterventional Surgery: 12/4/12 The world of intra-arterial therapy for acute ischemic stroke is currently in a state of flux. The IMS-3 trial (randomized trial comparing intravenous therapy with combined intravenous–intra-arterial therapy) was recently stopped prior to completion due to futility. A number of similar trials have either been started (THERAPY and others) or being […]
Clinical Trials
Friday, December 7th, 2012
AHA: December 3, 2012 Background—We sought to define the factors associated with the occurrence of stroke and systemic embolism in a large, international atrial fibrillation (AF) trial. Methods and Results—In ROCKET AF, 14,264 patients with nonvalvular AF and creatinine clearance (CrCl) ≥30 mL/min were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards modeling was used […]
Clinical Trials
Friday, December 7th, 2012
AHA: November 29, 2012 Background and Purpose—Optimal timing of tracheostomy in ventilated patients with severe stroke is unclear. We aimed to investigate feasibility, safety, and potential advantages of early tracheostomy in these intensive care unit (ICU) patients. Methods—This prospective, randomized, parallel-group, controlled, open, and outcome-masked pilot trial was conducted in neurological/neurosurgical ICUs of a university […]
Clinical Trials
Saturday, December 1st, 2012
Oxfordjournals: 11/27/12 Aims Digoxin is frequently used for rate control of atrial fibrillation (AF). It has, however, been associated with increased mortality. It remains unclear whether digoxin itself is responsible for the increased mortality (toxic drug effect) or whether it is prescribed to sicker patients with inherently higher mortality due to comorbidities. The goal of our study […]
Clinical Trials
Saturday, December 1st, 2012
AHA: 11/20/12 Background—Atrial fibrillation (AF) is less prevalent in women versus men, but associated with higher risks of stroke and death in women. The role hormone therapy plays in AF is not well understood. Methods and Results—The Women’s Health Initiative (WHI) randomized postmenopausal women to placebo or conjugated equine estrogens (CEE; 0.625 mg/d) plus medroxyprogesterone acetate […]
